• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic.

作者信息

Chakraborty Chiranjib, Bhattacharya Manojit, Chopra Hitesh, Bhattacharya Prosun, Islam Md Aminul, Dhama Kuldeep

机构信息

Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal.

Department of Zoology, Fakir Mohan University, VyasaVihar, Balasore, Odisha.

出版信息

Int J Surg. 2023 Apr 1;109(4):1037-1040. doi: 10.1097/JS9.0000000000000219.

DOI:10.1097/JS9.0000000000000219
PMID:37097619
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10132299/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/145c/10389549/b26f1d624b7d/js9-109-1037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/145c/10389549/b26f1d624b7d/js9-109-1037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/145c/10389549/b26f1d624b7d/js9-109-1037-g001.jpg

相似文献

1
Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic.最近出现的奥密克戎亚变体BF.7及其RBD区域的R346T突变显示出更强的传播性和对中和抗体的更高抗性：在中国病例不断增加以及担心引发新一轮新冠疫情大流行的当前情况下，有必要进一步了解相关情况。
Int J Surg. 2023 Apr 1;109(4):1037-1040. doi: 10.1097/JS9.0000000000000219.
2
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.奥密克戎变异株 BQ.1、BQ.1.1、BA.4.6、BF.7 和 BA.2.75.2 增强型中和抗性。
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.
3
Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China.关于呼和浩特市感染新冠病毒奥密克戎变异株的 COVID-19 患者临床严重程度和流行病学分析的回顾性研究。
BMC Infect Dis. 2024 Feb 15;24(1):206. doi: 10.1186/s12879-024-09084-8.
4
Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant.BF.7 比其他奥密克戎亚型更具传染性吗？来自 BF.7 刺突 RBD 变异的结构和模拟研究的见解。
Int J Biol Macromol. 2023 May 31;238:124154. doi: 10.1016/j.ijbiomac.2023.124154. Epub 2023 Mar 24.
5
Omicron variant evolution on vaccines and monoclonal antibodies.奥密克戎变异株对疫苗和单克隆抗体的影响。
Inflammopharmacology. 2023 Aug;31(4):1779-1788. doi: 10.1007/s10787-023-01253-6. Epub 2023 May 19.
6
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.RBD-mRNA 疫苗诱导针对奥密克戎和多种其他变体的广泛中和抗体，并保护小鼠免受 SARS-CoV-2 挑战。
Transl Res. 2022 Oct;248:11-21. doi: 10.1016/j.trsl.2022.04.007. Epub 2022 Apr 28.
7
Policy choices for Shanghai responding to challenges of Omicron.上海应对奥密克戎挑战的政策选择。
Front Public Health. 2022 Aug 9;10:927387. doi: 10.3389/fpubh.2022.927387. eCollection 2022.
8
Omicron BA.5 Subvariant Provokes the Fifth COVID-19 Wave in Mexico: Closer to the End of This Pandemic.奥密克戎BA.5亚变体在墨西哥引发第五波新冠疫情：这场大流行接近尾声。
Disaster Med Public Health Prep. 2023 Jan 11;17:e344. doi: 10.1017/dmp.2023.14.
9
Current surge of COVID-19 infection in China and its impact on India.中国当前 COVID-19 感染的激增及其对印度的影响。
Indian J Med Microbiol. 2023 Mar-Apr;42:46-48. doi: 10.1016/j.ijmmb.2023.01.010. Epub 2023 Feb 2.
10
Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022.基于截至 2022 年 3 月 1 日中国所有本地疫情的发病数据，比较不同 COVID-19 株的流行病学特征和传播性。
Front Public Health. 2022 Sep 15;10:949594. doi: 10.3389/fpubh.2022.949594. eCollection 2022.

引用本文的文献

1
Population-level toggling of T cell immune escape at human leukocyte antigen anchor residues in SARS-CoV-2 Spike proteins, in an ethnically diverse population region.在一个种族多样化的人群区域中，SARS-CoV-2刺突蛋白中人类白细胞抗原锚定残基处T细胞免疫逃逸的群体水平切换。
PLoS Comput Biol. 2025 Jul 21;21(7):e1013261. doi: 10.1371/journal.pcbi.1013261. eCollection 2025 Jul.
2
Comprehensive analysis of SARS-CoV-2 Spike evolution: epitope classification and immune escape prediction.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白进化的综合分析：表位分类与免疫逃逸预测
Virus Evol. 2025 Jun 11;11(1):veaf027. doi: 10.1093/ve/veaf027. eCollection 2025.
3
Changes in children respiratory infections pre and post COVID-19 pandemic.
新冠疫情前后儿童呼吸道感染的变化。
Front Cell Infect Microbiol. 2025 Apr 7;15:1549497. doi: 10.3389/fcimb.2025.1549497. eCollection 2025.
4
Detection of SARS-CoV-2 in wastewater as an earlier predictor of COVID-19 epidemic peaks in Venezuela.从废水中检测 SARS-CoV-2 可作为预测委内瑞拉 COVID-19 疫情高峰的早期指标。
Sci Rep. 2024 Nov 8;14(1):27294. doi: 10.1038/s41598-024-78982-3.
5
Effectiveness of COVID-19 Vaccination against Severe Symptoms and Death Among Geriatric Inpatients: A Retrospective Cohort Study in Macao.新冠病毒疫苗对老年住院患者严重症状和死亡的有效性：澳门的一项回顾性队列研究
Vaccines (Basel). 2024 Aug 21;12(8):933. doi: 10.3390/vaccines12080933.
6
A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety.新型冠状病毒2变种与疫苗综述：病毒特性、突变、疫苗效力及安全性
Infect Med (Beijing). 2023 Sep 12;2(4):247-261. doi: 10.1016/j.imj.2023.08.005. eCollection 2023 Dec.
7
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.人源化单克隆抗体 F61 鼻喷剂在 2022 年末至 2023 年初的 COVID-19 大流行期间，有效地保护了中国的高风险人群免受 SARS-CoV-2 变异株的侵害。
Emerg Microbes Infect. 2024 Dec;13(1):2284297. doi: 10.1080/22221751.2023.2284297. Epub 2024 Mar 26.